- Home
- ORIC vs DVAX Comparison
ORIC vs DVAX Comparison
Compare ORIC & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORIC
- DVAX
- Stock Information
- Founded
- ORIC 2014
- DVAX 1996
- Country
- ORIC United States
- DVAX United States
- Employees
- ORIC N/A
- DVAX N/A
- Industry
- ORIC Biotechnology: Pharmaceutical Preparations
- DVAX Biotechnology: Pharmaceutical Preparations
- Sector
- ORIC Health Care
- DVAX Health Care
- Exchange
- ORIC Nasdaq
- DVAX Nasdaq
- Market Cap
- ORIC 1.1B
- DVAX 1.2B
- IPO Year
- ORIC 2020
- DVAX 2004
- Fundamental
- Price
- ORIC $12.20
- DVAX $11.08
- Analyst Decision
- ORIC Strong Buy
- DVAX Buy
- Analyst Count
- ORIC 8
- DVAX 4
- Target Price
- ORIC $17.86
- DVAX $26.50
- AVG Volume (30 Days)
- ORIC 1.1M
- DVAX 1.7M
- Earning Date
- ORIC 11-13-2025
- DVAX 11-05-2025
- Dividend Yield
- ORIC N/A
- DVAX N/A
- EPS Growth
- ORIC N/A
- DVAX N/A
- EPS
- ORIC N/A
- DVAX N/A
- Revenue
- ORIC N/A
- DVAX $330,514,000.00
- Revenue This Year
- ORIC N/A
- DVAX $23.23
- Revenue Next Year
- ORIC N/A
- DVAX $16.57
- P/E Ratio
- ORIC N/A
- DVAX N/A
- Revenue Growth
- ORIC N/A
- DVAX 26.73
- 52 Week Low
- ORIC $3.90
- DVAX $9.20
- 52 Week High
- ORIC $14.93
- DVAX $14.63
- Technical
- Relative Strength Index (RSI)
- ORIC 46.07
- DVAX 61.75
- Support Level
- ORIC $12.02
- DVAX $9.92
- Resistance Level
- ORIC $13.04
- DVAX $11.43
- Average True Range (ATR)
- ORIC 0.75
- DVAX 0.35
- MACD
- ORIC -0.12
- DVAX 0.08
- Stochastic Oscillator
- ORIC 20.69
- DVAX 75.83
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.